Interleukin-22 (IL-22) is a critical cytokine belonging to the IL-10 family, playing dual roles in tissue repair and inflammatory pathologies. Acting through its heterodimeric receptor complex (IL-22R1 and IL-10R2), IL-22 mediates epithelial barrier protection, tissue regeneration, and antimicrobial host defense, making it a highly sought-after target. The therapeutic pipeline is split between IL-22 agonists (e.g., IL-22-Fc fusion proteins) for inflammatory bowel disease (IBD), acute pancreatitis, and graft-versus-host disease (GvHD), and IL-22 antagonists (blocking antibodies) for autoimmune diseases like psoriasis and atopic dermatitis.
TarMart Solution Ecosystem & Related Targets
To support both agonist and antagonist drug development pipelines, TarMart offers a comprehensive suite of sequence-verified, high-purity reagents designed to validate target binding, receptor dimerization, and downstream signaling pathways.
"Comprehensive reagent toolkit for IL-22 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-22 Recombinant Protein (HEK293-expressed, Native Glycosylation) High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. Available in Human, Mouse, and Cynomolgus orthologs. |
View IL22 Products |
| Gene Delivery | IL-22 Lentivirus / Promise-ORF Full-length ORF for stable cell line generation and expression validation. |
View IL22 Products |
| Benchmark Ab | Anti-IL-22 Recombinant Antibody (Fezakinumab Sequence) Recombinant human IgG1 positive control for neutralization and binding assays. |
View IL22 Products |
| Validator | IL-22 siRNA Set Target-specific knockdown pool for functional specificity validation. |
View IL22 Products |
| Related Target A | IL-22R1 (Interleukin-22 Receptor Subunit Alpha 1) Primary high-affinity receptor subunit for binding specificity and competition assays. |
View IL22R1 Products |
| Related Target B | IL-10R2 (Interleukin-10 Receptor Subunit Beta) Required accessory receptor subunit for functional heterodimerization and signal transduction. |
View IL10R2 Products |
| Related Target C | IL-22BP (IL-22 Binding Protein / IL22RA2) Natural soluble decoy receptor; critical for screening selectivity and physiological regulation studies. |
View IL22BP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus IL-22 recombinant proteins verified by SDS-PAGE and Mass Spectrometry to guarantee ortholog cross-reactivity. |
| Receptor Dimerization & Competition Screening | Highly pure monomeric IL-22R1 and IL-10R2 extracellular domains (ECD) to map precise binding epitopes of blocking antibodies. |
| Lack of Controls for Neutralization Assays | Fezakinumab-sequence biosimilar antibody provided as an absolute functional benchmark. |
| False Positive Knockdown Signals | Sequence-validated siRNA pools to confirm target-specific phenotypic changes in epithelial cell lines. |
Live IL-22 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-22 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to tissue-targeted agonists and localized delivery systems. As first-generation therapies reach the clinic, the next wave of R&D is targeting mucosal healing in inflammatory bowel disease (IBD) and tissue protection in acute organ injuries, such as severe alcoholic hepatitis and acute pancreatitis. Conversely, neutralizing anti-IL-22 agents are being positioned to treat chronic inflammatory skin disorders where IL-22 drives pathological epithelial hyperplasia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fc-Fusion Protein (Agonist) | Generon (Evive Biotech), Tasly Pharmaceutical | Severe Alcoholic Hepatitis, IBD, GvHD | STAT3 Phosphorylation Assays (Need high-purity, bioactive-grade IL-22 and receptor proteins) |
| Monoclonal Antibody (Antagonist) | Pfizer, Amgen | Atopic Dermatitis, Psoriasis | Ligand-Receptor Blocking Assays (Need recombinant IL-22R1 and IL-10R2 ECD proteins) |
| Bispecific Antibodies | Academic & Biotech Consortia | Autoimmune Diseases, Colorectal Cancer | Dual-target binding kinetics (Need multi-species ortholog panels) |